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Human stem cell-derived 
retinal epithelial cells activate 
complement via collectin 11 in 
response to stress
Giorgia Fanelli1, Anai Gonzalez-Cordero2, Peter J. Gardner  2, Qi Peng1, Milan Fernando2, 
Magdalena Kloc2, Conrad A. Farrar1, Arifa Naeem2, Peter Garred3, Robin R. Ali2 & Steven H. Sacks1
Age-related macular degeneration (AMD) is a major cause of blindness and is associated with 
complement dysregulation. The disease is a potential target for stem cell therapy but success is 
likely to be limited by the inflammatory response. We investigated the innate immune properties 
of human induced-pluripotent stem cell (iPSC)-derived RPE cells, particularly with regard to the 
complement pathway. We focused on collectin-11 (CL-11), a pattern recognition molecule that 
can trigger complement activation in renal epithelial tissue. We found evidence of constitutive and 
hypoxia-induced expression of CL-11 in iPS-RPE cells, and in the extracellular fluid. Complement 
activation on the cell surface occurred in conjunction with CL-11 binding. CL-11 has been shown to 
activate inflammatory responses through recognition of L-fucose, which we confirmed by showing 
that fucosidase-treated cells, largely, failed to activate complement. The presence of CL-11 in healthy 
murine and human retinal tissues confirmed the biological relevance of CL-11. Our data describe a new 
trigger mechanism of complement activation that could be important in disease pathogenesis and 
therapeutic interventions.
The retinal pigment epithelium (RPE) consists of a monolayer of cells situated between the photoreceptor cells 
and the choroid and plays a critical role in the visual cycle, maintaining the health of photoreceptor cells by pro-
viding nutrients, growth factors and by continually phagocytosing photoreceptor outer segment discs. Together 
with Bruch’s membrane, tight junctions between neighboring RPE cells form the outer blood-retinal barrier, 
which is essential for maintaining retinal homeostasis. Loss of RPE cells and the subsequent loss of photoreceptor 
cells they support is associated with degenerative diseases such as Stargardt’s disease, retinitis pigmentosa and 
age-related macular degeneration (AMD), the leading cause of blindness in the developed world1. Current ther-
apies for AMD are only effective in reducing aberrant blood vessel formation in neovascular AMD and there is 
no therapy for geographic atrophy, an advanced non-vascular form that comprises a third of all late-stage AMD 
patients2. A growing body of evidence suggests that choroidal blood flow is reduced in AMD3,4 and data from 
transgenic mouse models where HIF (hypoxia-inducible factor) pathways are specifically activated in RPE show 
photoreceptor degeneration and features consistent with some aspects of AMD pathology5. As HIF pathways are 
linked to inflammation6 it is possible that some of the chronic dysregulation of local para-inflammatory responses 
in the eye associated with AMD7–9 may be driven by RPE hypoxic stress resulting in the aberrant activation of 
complement on host cells. Regrettably, how complement system dysregulation in retina can lead to cell and tissue 
damage under inflammatory conditions, including AMD, has not yet been addressed. Circulating levels of C3a, 
C3d and C5a, have been found in AMD patients10,11 indicating enhanced local complement activation. Moreover, 
polymorphisms in a number of complement genes such as, CFH, C3, CFB and C2, have been shown to be asso-
ciated with AMD12–14 suggesting that the complement system, in particular the alternative pathway, may be dys-
regulated in AMD patients. Therefore, appropriate control of local complement activation may preserve retinal 
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structure and function. Since RPE loss is a major component of AMD pathogenesis, there is major interest in the 
development of treatment strategies involving the replacement of this monolayer by grafting healthy RPE under 
the macula1. A number of studies have demonstrated preservation of visual function following the transplanta-
tion of stem cell–derived RPE into animal models of retinal degeneration15,16. The trials to date suggest that the 
transplanted cells are well tolerated and are not tumorogenic17–19. Although the eye is immune privileged, this is 
likely to provide a limited advantage for RPE transplantation and thus further studies are required to determine 
whether and under what circumstances the cells might provoke host immune responses.
Collectin 11 (CL-11, also known as collectin-kidney 1 or CL-K1 and is encoded by COLEC11) is a recently 
described soluble C-type lectin of innate defence20,21. It belongs to the group of collectins that include the sur-
factant proteins SP-A and SP-D, mannose-binding lectin (MBL), collectin liver 1 (CL-10 or CL-L1) and collectin 
placenta 1 (CL-12 or CL-P1)22,23. The structure and function of CL-11 are similar to MBL regarding the binding 
to carbohydrates on pathogens and activating MBL-associated serine proteases (MASPs) to initiate the lectin 
pathway of complement activation21,24, resulting in the generation of complement activation products includ-
ing the membrane attack complex (MAC) formation and targeted cell death. An important difference, however, 
is that while the large macromolecular complexes of MBL in the serum are mainly produced by hepatic syn-
thesis25, CL-11 is primarily generated by parenchymal cells in the extravascular compartment26,27. It has been 
recently demonstrated that CL-11 activates a destructive inflammatory response through recognition of L-fucose 
on post-ischemic renal tubule cells close to the site of CL-11 production28. Although the adrenal glands, kidney 
and liver are the main expression sites of human CL-1127,29, moderate levels of CL-11 were also found in the 
ovaries, testis and retina20. In this study we investigated the role of CL-11 on human iPS-RPE cells by examin-
ing the interplay between cell hypoxia and local induction of CL-11 binding and complement activation on the 
hypoxia-stressed cells. A more detailed knowledge of this relationship may provide insights for understanding the 
potential inflammatory and immune responses of the host environment to stem cell derived-RPE cells following 
transplantation.
Results
CL-11 is expressed in the human eye with similar expression found in iPS-RPE cells as in endog-
enous RPE. Although transcription of CL-11 has been reported in the human retina20, its expression in the 
eye has not been explored in detail. Here, we investigated the expression pattern of CL-11 on human retinal 
sections by confocal microscopy. The specificity of the anti-human CL-11 antibody was validated by immuno-
histochemical staining of Colec11+/+ and Colec11−/− mouse eye sections (Supplemental Fig. 1a). As illustrated 
in Fig. 1a, permeabilisation to allow detection of both surface-bound and intracellular CL-11 revealed staining 
throughout several of the retinal layers, in peripheral as well as central retinal regions. Expression of CL-11 was 
particularly strong in the photoreceptor inner segments, in the cell inner and outer plexiform layers and in the 
nerve fibre layer of the ganglion cell layer. Positive labelling for CL-11 above background autofluorescence of 
pigment was also evident in the RPE layer and in the choroid, best seen at the higher magnification. Cell surface 
staining of CL-11 was present but fainter throughout the retina and RPE suggesting a predominant intracellular 
expression pattern (Fig. 1a), whereas within the choroid CL-11 was largely absent from the surface of cells. In 
contrast to the retina, intense CL-11 staining was observed in the anterior uvea section, iris and ciliary body, on 
both permeabilised and non-permeabilised sections (Supplemental Fig. 2).
Having detected CL-11 expression in the eye, we then determined whether CL-11 was also present on dif-
ferentiated human iPS-RPE cells, a potential source for RPE replacement in patients with AMD and inherited 
retinal degeneration. As shown in Fig. 1b, cultured cells displayed the classic cobblestone pigmented morphol-
ogy. Following permeabilisation, the iPS-RPE cells grown under steady state conditions displayed a pronounced 
intracellular staining pattern for CL-11 (Fig. 1b,c), whereas the expression on the cell surface was markedly 
lower (Fig. 1c). The same pattern of expression was observed on primary cultures of adult murine RPE cells 
(Supplemental Fig. 1b,c). Our data confirm that CL-11 is expressed in the human and mouse eye and reveal that 
human iPS-RPE cells show a pattern of surface and intracellular expression of CL-11 that is similar to adult RPE.
Effect of hypoxic stress on cultured human iPS-RPE cells. The concentration of oxygen in human 
tissues varies from 3 to 5% and a decline below this range is considered as hypoxia30. In macular degeneration, 
progression of disease is associated with hypoxia due to disruption in the underlying choroid and perturbations 
in retinal blood flow31,32. Therefore we sought to develop an in vitro model of hypoxia-induced stress on cultured 
human iPS-RPE cells. To induce hypoxia, we maintained cultured iPS-RPE cells in 1% oxygen in a controlled 
chamber for 24 hours. We first confirmed that the cells were hypoxic. Immunofluorescence analysis showed pos-
itive nuclear staining with a hypoxia-specific probe (Fig. 2a) and up-regulation of the hypoxia-inducible factor 
HIF2 under hypoxic conditions (Fig. 2b). Furthermore, western blot analysis demonstrated a significant increase 
in HIF-1α confirming that iPS-RPE cells were sensitive to hypoxic stress (Fig. 2c). Prolonged hypoxia can lead 
to cell death, thus we assessed the viability of the cells cultured under normal and hypoxic conditions following 
24-hours hypoxia33. Flow cytometry analysis showed no discernable difference in cell death in both of these con-
ditions (Fig. 2d). Finally, we checked the morphological appearance and the presence of RPE-specific markers 
following hypoxic stress. No major changes were observed in the hypoxic iPS-RPE cells. The typical cobblestone 
RPE morphology was still intact as demonstrated by staining of the ZO-1 tight junction protein. The expression 
of BESTROPHIN and OTX2 decreased following hypoxic stress whereas no noticeable differences were observed 
in the other RPE markers tested (Fig. 2e).
Hypoxia-stressed iPS-RPE cells show increased expression, secretion and L-fucose-mediated 
surface binding of CL-11. Adequate complement regulation in the eye is a conditio sine qua non to prevent 
tissue injury34. However, alteration in the expression of complement regulators on the surface of RPE cell line 
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can occur following cellular stress35. In the present study, we examined whether hypoxic stress could affect the 
expression of CL-11 in human iPS-RPE cells and whether this led to increased CL-11 binding on the surface of 
these cells. Western blot analysis showed that the amount of CL-11 protein in iPS-RPE cells following hypoxia 
was comparable to those cells cultured under normal level of oxygen (Fig. 3a,b). However, soluble CL-11 was 
detectable in the supernatants of hypoxic iPS-RPE cells (Fig. 3c) suggesting CL-11 release following hypoxic 
cell stress. To investigate the presence of CL-11 at the surface of iPS-RPE cells, we performed immunofluores-
cence staining of CL-11 on non-permeabilised iPS-RPE cells under normal or hypoxic conditions, as previously 
described. We observed that CL-11 detection was significantly higher on the surface of hypoxia–stressed iPS-RPE 
cells compared to normoxic cells (Fig. 3d,e) suggesting that iPS-RPE cells are able to produce, secrete and bind 
CL-11 following hypoxic stress.
The binding of CL-11 to renal tubular epithelial cell surface is mediated through the recognition of L-fucose, 
the preferred ligand for both human and murine CL-1120,26,29. As it has been shown that retinal pigment epithe-
lium contains glycoconjugates rich in α-Fuc36, we examined whether L-fucose could be recognised by CL-11 on 
stressed-iPS-RPE cells. The merged immunofluorescence image in Fig. 3f shows co-localization of CL-11 and 
L-fucose on the surface of non-permeabilised hypoxia-stressed iPS-RPE cells, suggesting that L-fucose is bound 
in an autocrine manner by CL-11 secreted by stressed iPS-RPE cells. To verify that L-fucose acts as a ligand for 
CL-11, we treated human iPS-RPE cells with fucosidase to specifically remove L-fucose from the cell surface. 
As expected, the fucosidase-treated cells showed a dramatic decrease of L-fucose expression and CL-11 binding 
confirming the co-localization of these two molecules on hypoxia-stressed iPS-RPE cells (Fig. 3f,g,h).
Complement activation triggered by CL-11 results in C3 binding and MAC detection on 
hypoxia-stressed iPSC-RPE cells. Epithelial cells from different organs can respond to cellular stress in 
an idiosyncratic manner. In fact, aberrant complement activation on epithelial barrier layers is a hallmark of 
inflammatory diseases in several organs, including the kidney37, the lung38 and the eye39. Therefore, we inves-
tigated whether locally produced CL-11 was able to initiate complement activation on iPS-RPE cells following 
hypoxia-induced cell stress. We measured the expression of the central complement component C3 in iPS-RPE 
Figure 1. Human retina tissue expression and iPS-RPE cell expression patterns of CL-11. (a) Representative 
confocal image showing CL-11 expression on permeabilised (left panel) and non-permeabilised (middle panel) 
human retinal sections. The sections shown are taken from the peripheral retina and from the central retina 
outside the macula. Control sections were incubated with no primary antibody (right panel). CL-11 (green), 
nuclei (blue) and autofluorescence (red) are shown. Scale bars, 25 μm. CL-11 staining without DAPI is shown 
on the right side of peripheral retina and central retina panels. High magnification images of area indicated in 
the white box are shown in the bottom panel. Scale bar, 10 μm. (b) Representative confocal microscopic image 
showing differentiated iPS-RPE cells morphology (left panel) and CL-11 staining on permeabilised human iPS-
RPE cells (middle and right panel). CL-11 (red), nuclei (blue) and phalloidin (aqua) are shown. Scale bars, 25 
μm (c) Flow cytometry histograms showing CL-11 expression on permeabilised iPS-RPE cells (intracellular) 
versus non-permeabilised cells (surface). Cells stained with secondary antibody alone were used as control.
www.nature.com/scientificreports/
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cells grown in the absence of foetal bovine serum under normal or hypoxic conditions. Although we did not 
detect any major changes in C3 protein (both α-chain and β-chain) expression in non-hypoxic versus hypoxic 
iPS-RPE cells (Fig. 4a), immunofluorescence analysis revealed a significant increase of the activated fragment 
C3d, formed after cleavage of C3, on the surface of hypoxia-stressed iPS-RPE cells (Fig. 4b,c). Under hypoxic con-
ditions, high levels of CL-11 were observed on the cell surface as well C3d deposition (Fig. 4d). C3d was mainly 
co-localised with CL-11 on the surface (Fig. 4b). Quantification of the co-localization of C3d with CL-11 using 
Mander’s co-localization coefficient showed clearly the level of association of two molecules on the cell surface 
(Fig. 4e). This result highlights the relationship of these two molecules indicating strong complement deposi-
tion at the site of CL-11 binding. Of interest, many of the bright spots corresponding to strong areas of C3d and 
CL-11 co-localisation are surrounded by a more diffuse punctate pattern for C3d staining, which could suggest 
Figure 2. iPS-RPE cell viability and phenotype following hypoxic stress. (a) Immunohistochemistry images 
showing RPE cells treated with hypoxyprobe and antibody stained for probe detection. A competed antibody 
(background staining) was used as control. (b) Images showing iPS-RPE cells stained for HIF2 in normoxia 
and hypoxia conditions. Nuclei are counterstained with DAPI (blue). Scale bars, 25 μm (c) Western blot 
analysis showing up-regulation of HIF-1α following 24 hours  of hypoxic stress compared to non-stressed cells. 
N = 5 independent experiments *P < 0,05, t-test. Full-length blots are presented in Supplemental Fig. 3. (d) 
Representative FACS plots showing the viability of iPS-RPE cells following or not hypoxic stress using the Live/
Dead assay. (e) Representative confocal images showing iPS-RPE phenotype following or not hypoxic stress. 
Cells were stained for: OTX2, Bestrophin, ZO-1, RPE65, EZRIN, CRALBP and Phalloidin. Scale bars, 25 μm.
www.nature.com/scientificreports/
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Figure 3. CL-11 binding to hypoxia-stressed iPS-RPE cells. (a) Representative Western blot under reducing 
conditions showing CL-11 expression in iPS-RPE cells under normal and hypoxic conditions. HSP90 was 
used as a loading control. Full-length blots are presented in Supplemental Fig. 4. (b) Relative density analysis 
of CL-11 in iPS-RPE cells following different treatments (N = 3 independent experiments). (c) Detection of 
both non-reduced (100 kDa) and reduced states (34 kDa) of CL-11 in the culture supernatants of iPS-RPE cells 
following or not hypoxic stress by Western blotting. (d) Representative immunofluorescence images showing 
CL-11 binding to the surface of hypoxic-stressed iPS- RPE cells compared to non-stressed cells. Scale bars, 25 
μm. (e) Quantification of CL-11 binding in normal and hypoxic iPS-RPE cells using ImageJ software. CL-11 
(red), nuclei (blue) and phalloidin (aqua) are shown. N = 3 independent experiments, ***P < 0,0001, t-test. (f) 
Confocal images of CL-11 (red) and L-fucose (green) showing co-expression of CL-11 and L-fucose (orange) on 
hypoxic–iPS-RPE cells treated or untreated with fucosidase. Scale bars, 50 μm. (g) Quantification of L-fucose 
expression and (h) CL-11 binding to hypoxia-stressed cells treated or untreated with fucosidase using ImageJ 
software. N = 4 independent experiments.
www.nature.com/scientificreports/
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Figure 4. C3d deposition and Mac assembly on hypoxia-stressed iPS-RPE cells. (a) Representative Western 
blot showing C3 protein expression in iPS-RPE cells under normal and hypoxic conditions. Actin was used as a 
loading control. Full-length blots are presented in Supplemental Fig. 5. (b) Representative immunofluorescence 
images showing CL-11 (red) and C3d (green) staining on hypoxia-stressed iPS- RPE cells compared to non-
stressed cells. Nuclei (blue) and phalloidin (grey) are shown. Scale bars, 25 μm. Quantification of CL-11 (c) 
and C3d (d) expression following or not hypoxia stress using ImageJ software. N = 3 independent experiments; 
n = 15 images analysed ***P < 0,0001, t-test. (e) CL-11 and C3d co-localization was quantified by calculating 
Mander’s co-localization coefficients using JACoP plug-in and ImageJ software. (f) Representative confocal 
images of CL-11 (green), MAC (red) nuclei (blue) and phalloidin (aqua) showing co-expression of CL-11 and 
MAC on hypoxic iPS-RPE compared to non-stressed cells. Scale bars, 25 μm. High magnification image (white 
box) showing co-localization of CL-11 and MAC. Scale bars, 10 μm. (g) CL-11 and MAC co-localization was 
quantified by calculating Mander’s co-localization coefficients using JACoP plug-in and ImageJ software. N = 3 
independent experiments.
www.nature.com/scientificreports/
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complement activation is triggered at focal sites where CL-11 is bound and is amplified circumferentially by the 
alternative pathway in a CL-11 independent fashion.
In order to further characterize the pathophysiological role of CL-11, we tested whether this molecule under 
stress conditions was able to trigger membrane attack complex (MAC) formation on iPS-RPE cells. MAC, or 
C5b-9, is the terminal complex of the complement cascade that forms a lytic pore on the surface of target cell 
membranes inducing cell lysis and inflammatory responses40–42. In AMD, it is known that MAC assembles on 
RPE cells43,44 and the amount of MAC deposition is correlated with the loss of RPE cells45,46. Therefore, we tested 
the ability of iPS-RPE cells to produce the final component of the MAC complex, C9, under normal or hypoxic 
conditions by Luminex methodology. We detected low levels of C9 monomers only in the supernatants of the 
iPS-RPE cells cultured under normal conditions (data not shown). However, MAC positive staining was observed 
on hypoxia-stressed iPS-RPE cells compared to non-stressed cells suggesting that C9 molecules were incorpo-
rated into the terminal complex (Fig. 4f,g). Some areas showed co-localization of CL-11 with MAC whereas in 
other areas the relationship between MAC and CL-11 was less precise. Overall these results suggest that MAC 
formation on the iPS-RPE cells was triggered by hypoxia-induced CL-11 binding and complement activation.
Removal of L-fucose ligand recognised by CL-11 results in less C3d deposition and MAC forma-
tion on stressed cells. To better understand the role of L-fucose to mediate CL-11 binding and complement 
activation, we carried out experiments with hypoxia-stressed iPS-RPE cells treated with fucosidase, as described 
above (Fig. 3f). As shown in Fig. 5a,b, fucosidase-treatment dramatically decreased C3d deposition and MAC 
assembly (Fig. 5c) on the surface of hypoxia—stressed iPS-RPE cells. By contrast, untreated cells retained C3d 
and MAC staining under stress conditions. Taken together with the data represented in Fig. 3g,h, this result 
Figure 5. C3d expression and MAC formation on hypoxia-stressed iPS-RPE cells following fucosidase 
treatment. (a) Representative immunofluorescence images showing C3d deposition on the surface of 
hypoxia-stressed iPS-RPE cells treated or not overnight with fucosidase. C3d (green), nuclei nuclei (blue) 
and phalloidin (grey) are shown. Scale bars, 50 μm. (b) Quantification of C3d expression level on hypoxia-
stressed iPS- RPE cells compared to fucosidase-treated hypoxic cells using ImageJ software. (c) Representative 
immunofluorescence images showing MAC staining on the surface of hypoxia-stressed iPS-RPE cells treated or 
not overnight with fucosidase. MAC (red), nuclei (blue) and phalloidin (grey) are shown. Scale bars, 50 μm.
www.nature.com/scientificreports/
8SCIeNTIfIC REPoRTS | 7: 14625  | DOI:10.1038/s41598-017-15212-z
supports the notion that CL-11 bound to the surface of hypoxia-stressed iPS-RPE cells acts a trigger for C3d dep-
osition and consequentially causes MAC formation on the surface of hypoxia-stressed iPS-RPE cells.
CL-11 associated with MASP-2 drives complement activation on hypoxia-stressed iPS-RPE 
cells. CL-11 circulates as complexes with MBL/ficolin, CL-associated serine proteases, MASP-1, MASP-2 
and MASP-3 that, following the binding to pathogens, cleave C4 and C2 to generate the classical C4b2a con-
vertase and initiate complement activation20,21. In addition, it has been demonstrated, in models of cardiac, 
intestinal and renal reperfusion injury, that MASP-2 is a crucial mediator of tissue injury and can cleave C3 
independently of C447–49. Under normal culture conditions RPE cells express several complement components 
and regulators50; however the expression of MASP-2 has not previously been reported. We examined whether 
MASP-2 was expressed in iPS-RPE cells and whether CL-11 used MASP-2 to initiate complement activation on 
hypoxia-stressed iPS-RPE cells. As shown in Fig. 6a, Western blot analysis disclosed the expression of MASP-2 
in iPS-RPE cells; however no major differences were observed in normal cells versus hypoxic cells (Fig. 6b). 
Interestingly, prominent MASP-2 staining was detected in hypoxic iPS-RPE cells by immunofluorescence com-
pared to non-stressed cells (Fig. 6c). This prompted us to investigate whether CL-11 could interact with MASP-2 
on the surface of hypoxia-stressed iPS-RPE cells.
The immunofluorescent images for CL-11 and MASP-2 show there are numerous areas where these two mol-
ecules are co-located on RPE cells (Fig. 6d,e), though it is difficult to establish the precise extent of overlap due 
to the weaker staining of MASP-2 compared to CL-11. Nonetheless, having already shown CL-11 interaction 
with fucosylated ligand is required to deposit complement (Fig. 4b), the location of MASP-2 at the same place as 
CL-11 suggests a unifying mechanism in which complement activation on the hypoxia-stressed epithelial cells is 
dependent on the physical presence of MASP-2 at the CL-11-ligand interaction site.
Figure 6. CL-11 and MASP-2 interaction on hypoxia-stressed iPS-RPE cells. (a) Representative Western 
blot showing MASP-2 protein expression in iPS-RPE cells under normal and hypoxic conditions. HSP90 was 
used as a loading control. Full-length blots are presented in Supplemental Fig. 6. (b) Relative density analysis 
of MASP-2 in iPS-RPE cells under different treatments. N = 3 independent experiments. (c) Representative 
immunofluorescence images showing MASP-2 staining on hypoxia-stressed iPS- RPE cells compared to 
non-stressed cells. MASP-2 (red) and phalloidin (aqua) are shown on the left panels and MASP-2 (red) alone 
is shown on the right panels. Scale bars, 25 μm. (d) Representative immunofluorescence images showing co-
expression of CL-11 and MASP-2 (orange) on the surface of hypoxia-stressed iPS- RPE cells MASP-2 (red), 
CL-11 (green) nuclei (blue) and phalloidin (grey) are shown. Scale bars, 25 μm. (e) CL-11 and MASP-2 co-
localization was quantified by calculating Mander’s co-localization coefficients using JACoP plug-in and ImageJ 
software.
www.nature.com/scientificreports/
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Methods
Ethical statement. Human eye tissue used in this study was provided by Moorfields Biobank with support 
from NIHR funding. Informed consent was given for all anonymous tissue samples used and ethical approval was 
given by the NHS Research Ethics Committee (10/H0106/57–14ETR41). All methods were carried out in accord-
ance with guidelines and regulations as licensed by the HTA at the UCL Institute of Ophthalmology.
iPS-cell derived RPE differentiation culture. Human iPS stem cell lines (IRM90-4 from Wicell) were 
maintained on feeder free conditions on E8 (Thermo Fisher) and geltrex coated 6 well plates. Briefly, when 80% 
confluent hiPS were dissociated using a 1:1 dispase and collagenase solution for 10 minutes. iPS clumps were 
collected, washed twice with PBS and resuspended in E8 media for further maintenance culture on 6 well plates. 
Human iPS cells were maintained as described above until 90–95% confluent, then media without FGF (E6, 
Thermo Fisher) was added to the cultures for two days (D1 and 2 of differentiation) followed by a neural induc-
tion period (up to 7 weeks) in proneural induction media (PIM; Advanced DMEM/F12, MEM non essential 
amino acids, N2 Supplement, 100 mM Glutamine and Pen/Strep). Lightly- pigmented islands of RPE appeared as 
early as week 3 in culture. Media was then changed to retinal differentiation media (RDM; DMEM, F12, Pen/Strep 
and B27 without retinoic acid) until defined islands of RPE appeared. Pigmented areas of RPE were picked under 
the dissection microscope using a 21G needle, dissociated by trypsin and plated on laminin (BD Bioscience) 
coated 24 plate wells in RDM. Once confluent and pigmented cells were expanded up to two times for various 
experiments. Maintenance cultures of hPSCs were feed daily and differentiation cultures were feed every 2 days.
Immunohistochemistry. For human retinal sections human eyes collected by Moorfields Lions Eye Bank 
for corneal transplantation from anonymous donors were fixed in 10% formalin for 48 hours prior to processing 
and embedding in wax paraffin. 3 μm sections were cut and mounted on slides (Superfrost Ultra plus, Thermo 
Scientific). Following paraffin removal by Histo-Clear and re-hydration of slides, sections were subjected to anti-
gen retrieval by pressure cooker heating in low pH sodium citrate buffer (Antigen unmasking solution, Vector 
Labs H-3300). Sections were then blocked for 1 hour in blocking buffer (5% donkey serum) with or without 
Triton X-100 (2%) in PBS, followed by 1 hour at RT with primary antibodies diluted in blocking buffer. Sections 
were washed with PBS (2 × 5 minutes) and incubated with secondary antibody diluted in blocking buffer for 
1 hour at RT. Sections were then washed in PBS (2 × 5 minutes).
For staining of RPE cells human iPS-RPE cells were cultured either in glass chamber slides or in transwells 
and placed under hypoxic or normoxic conditions. Cells were fixed for 1 hour in 4% paraformaldehyde, blocked 
in 5% goat serum and 1% bovine serum albumin in PBS (block solution). Primary antibody was incubated over-
night at 4 °C. Sections were incubated with secondary antibody for 2 hours at RT, washed and counter-stained 
with DAPI (Sigma-Aldrich). Alexa fluor 488 and 546 secondary antibodies (Invitrogen-Molecular Probes) and 
Alexa fluor 633 Phalloidin (Thermo Fisher Scientific) were used at a 1:500 dilution. The following antibodies were 
used: mouse monoclonal anti- C3d, (1:100, Abcam); mouse monoclonal anti- C5b-9 (1:100, Abcam); polyclonal 
rabbit anti-human MASP-2 (1:100, Abcam), mouse monoclonal anti- RPE65 (1:200, Abcam), rabbit polyclonal 
anti ZO-1 (1:500, Thermo), mouse monoclonal anti-Bestrophin (1:300, Millipore/Merck), mouse monoclonal 
anti-CRALBP (1:300, Abcam), rabbit polyclonal anti-Otx2 (1:200, Abcam), rabbit polyclonal anti-EZRIN (1:100, 
Abcam) and rabbit polyclonal anti-HIF2 (1:100, Novus Biologicals).
For hypoxic probe experiments RPE cells were incubated with a 1:1 hydroxic probe (EF5; 10 mM in 0.9% 
saline solution; University of Pennsylvania, USA) solution in RDM media probe for 24 hours under hypoxia 
conditions (see below). Control cells were kept under normoxia. After treatment cells were fixed in 4% paraform-
aldehyde for 1 hour and incubated for 2 hours in blocking solution and incubated overnight in Cy3-conjugated 
ELK-351 antibody (diluted 1:1 in blocking buffer) at 4 °C. Staining controls (one unstained and one competed 
stain) were also prepared as per manufacturer’s instructions.
For all the above procedures Nuclei were stained DAPI (Sigma-Aldrich) for 5 minutes, washed with PBS 
and coverslip mounted with fluorescent mounting medium (DAKO, S3023). Images were acquired by confocal 
microscopy (Leica DM5500Q, Leica Microsystems).
Induction of hypoxic stress and cell viability. Human iPS-RPE cells were cultured under hypoxic con-
ditions (5% CO2, 1% O2 and 94% N2) in a gas chamber (Stem Cell Technologies) for 24 hours. Cell viability was 
measured using LIVE/DEAD Fixable Yellow Dead Cell Stain Kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Cells were analysed by flow cytometry using BD FACS CANTO II (BD Bioscience) 
and FlowJo software v9.7.5 for Mac.
Intracellular CL-11 staining in cultured iPS-RPE cells. iPS-RPE cells cultured on chamber slides, were 
fixed in 4% paraformaldehyde for 1 hour at room temperature and permeabilised with 3% Triton 1% BSA and 
5% serum for 2 hours. Cells were blocked in PBS 20% donkey serum (Sigma-Aldrich) for 30 minutes and incu-
bated with a rabbit polyclonal anti-CL-11 antibody (1:100, Abbexa) at 4 °C overnight. The slides were washed 
three times in PBS and incubated with secondary donkey anti-rabbit Alexa Fluor 488 (1:500, Abcam) or donkey 
anti-rabbit Alexa Fluor 594 (1:500, Invitrogen-Molecular Probes) for 1 hour at room temperature in the dark, and 
washed as described above. The nuclei were counterstained with DAPI (Sigma-Aldrich). The cells were washed, 
coated with mounting media (DAKO, S3023) and analysed by a Leica DM5500Q confocal microscopy.
Detection of CL-11 binding to cultured iPS-RPE cells. Cultured iPS-RPE cells were subjected to 
hypoxic stress as described before. Following 24 hours, the cells were washed in PBS and fixed in 4% paraform-
aldehyde (but not permeabilised) for 1 hour at room temperature. iPS-RPE cells were then stained for CL-11 by 
immunofluorescence using either rabbit polyclonal anti-CL-11 antibody (1:100, Abbexa) or a mouse monoclonal 
IgG anti-human CL-11 produced in house. The detection of L-fucose was achieved using Fluorescein ULEX 
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EUROPAEUS Agglutinin I (1:40). To remove L-fucose from cell surface, iPS-RPE cells were put under hypoxic 
conditions for 24 hours, fixed in 4% paraformaldehyde for 1 hour at room temperature and treated then with 
α1-2,3,4,6 fucosidase (New England BioLabs) at 37 °C overnight.
Western blotting. iPS-RPE cells were lysed in RIPA buffer (Thermo Fisher Scientific) containing protease 
inhibitor cocktail (Calbiochem), for 30 minutes on ice and centrifuged for 15 minutes at 14,000 x g. Protein con-
centrations were determined by Quick Start Bradford assay kit (Bio-Rad), according to the manufacturer’s instruc-
tions. Protein lysates were denatured by adding 2 × Laemmli buffer (Bio-Rad) containing 5% β-mercaptoethanol 
(Sigma). Protein samples (15–30 μg) were separated on 10% or 12% sodium dodecyl sulfate-polyacrylamide gels 
and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore). Membranes were blocked in 10% 
non fat dry milk (Bio-Rad) in PBS plus 0.1% Tween-20 for 30 minutes at room temperature and incubated with 
primary antibodies overnight at 4 °C, followed by three washes with PBS plus 0.1% Tween-20. Detection of the 
immunoreactive bands was performed with the ECL Western Blotting Substrate (Bio-Rad), and chemilumines-
cence was detected with the ImageQuant imaging system using anti-rabbit or anti-mouse HRP-linked antibody 
(Cell Signaling Technology) for 2 hours at RT. Primary antibodies raised against the following proteins were used 
for Western blotting: CL-11 (Abbexa, rabbit polyclonal), C3 (Abcam, mouse monoclonal), Actin (Santa-Cruz 
Rabbit polyclonal,), MASP-2 (Abcam, Rabbit polyclonal), HIF-1α (Abcam, Rabbit polyclonal) and HSP90α/β 
(Santa-Cruz Rabbit polyclonal). Culture supernatants of normal and hypoxic iPS-RPE cells were concentrated 50 
times using Vivaspin 6 ml 10,000MWCO spin columns (Sartorius) and analysed for CL-11 expression.
Flow cytometry. For detection of endogenous CL-11 expression, human iPS-RPE cells and primary murine 
RPE cells were treated with TrypLE Express enzyme solution (Thermo Fisher Scientific) for 10 minutes and 
single-cell suspensions were fixed and permeabilised (eBioscience) at 4 °C for 30 minutes. CL-11 staining was 
performed by preincubation of cells with 20% donkey serum for 30 minutes and then incubated with polyclonal 
rabbit anti-human CL-11 Ab (1:100), followed by donkey anti-rabbit Alexa Fluor 488 ab. Exogenous CL-11 bind-
ing was detected performing CL-11 staining without permeabilising the cells. Stained cells were analysed by flow 
cytometry using BD FACS CANTO II (BD Bioscience) and FlowJo software v9.7.5 for Mac.
Statistics. Regarding Immunohistology and Western Blotting, data are shown as mean ± standard error 
(SEM), unless otherwise noted. A paired, two-tail Student t-test was used to compare two groups. P-values below 
0.05 were considered significant. All analyses were performed using Graph Pad Prism, version 5 (GraphPad 
Software) and ImageJ software v1.51k for Mac with JACoP plugin.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Discussion
While transplantation of pluripotent stem cell derived-RPE cells is a promising approach to treat visual disor-
ders, a number of factors may impede success and these include the immune response against the transplanted 
cells and in particular the potential impact of hypoxia in the local environment during cell preparation or in 
the retinal niche. In this study we present evidence that the complement pattern recognition molecule CL-11 is 
broadly expressed in the human eye and in RPE cells generated from human skin fibroblasts (iPS-RPE cells). It 
is already known that several complement components and regulators can be expressed locally in the eye and 
that RPE cells are a major source of local complement expression51–54, suggesting that the retina has the capacity 
both to initiate and control local complement activation. Indeed, gene association studies in patient groups with 
AMD have indicated that allelic differences in the regulation of complement activation have a significant effect 
on disease pathogenesis55–57. Moreover, several in vitro studies have shown that the retinal complement machin-
ery is regulated by inflammatory cytokines and chemokines such as TNF-α, IFN-γ, IL-2758,59 or supernatants of 
macrophages containing proinflammatory factors50 indicating that the retinal complement system can actively 
respond to microenvironmental insults.
Here we demonstrate that cultured iPS-RPE cells have the capacity to produce, release and bind autocrine 
CL-11 under hypoxic cell stress. Our results also show that CL-11 released by stressed iPS-RPE cells is function-
ally active, since CL-11 expressed and bound by the cells was able to promote complement activation leading 
to C3 deposition and MAC formation on the cell surface. These data highlight that, although retinal cells may 
suppress inflammation under normal physiological conditions, in the presence of tissue insult, retinal cells could 
contribute to the local inflammatory response. Specifically, the results suggest that hypoxia-induced tethering of 
CL-11 to iPS-RPE cells can induce an inflammatory phenotype. Previously we have shown that renal epithelial 
cells of both human and murine origin also exhibit CL-11-dependent activation of complement in response to 
cell stress, suggesting that inflammatory signalling mediated by CL-11 is a conserved feature of epithelial cells of 
diverse origin28. Further work is needed to determine the potential impact on inflammasome activity of the cells 
and consequences for cell function during differentiation, antimicrobial defence and – of most relevance here – in 
the context of possible stem cell therapy applications. Moreover, our data imply that CL-11 driven complement 
activation may play a role in AMD pathophysiology.
Our data suggest that CL-11 can act in an autocrine or paracrine fashion, inducing iPS-RPE cell injury 
through complement pore formation and release of the small pro-inflammatory fragments C3a and C5a, pre-
sumed to occur following the cleavage of C3 and C5. Although differentiated iPS-RPE cells are morphologically 
and functionally close to native RPE cells, an important question for future work to resolve involves the extent to 
which inflammatory phenotype is affected by manipulation of the cells during cell culture or therapeutic adminis-
tration and whether this will have a significant bearing on cell viability, cell differentiation and cell immunogenic-
ity. Another key question is whether healthy stem cell derived-RPE cells transplanted into an inflamed eye, such 
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as in AMD patients, can be transformed into an inflammatory phenotype mediated by cell-endogenous CL-11, 
since the chronic retinal ischaemic environment can induce local cell death via complement activation and there-
fore potentially compromise the outcome of the transplant itself60–62. The inflammatory niche of the recipient 
retina could be important here. For example, adult hepatocytes and islet cells used for transplantation can induce 
a profound and immediate inflammatory response following contact with human serum, which is thought to 
involve triggering of the complement and coagulation cascades63–65. It will be essential to verify whether stem cell 
derived-RPE cells have similar properties and whether cell-protective therapy will be appropriate to enhance their 
utility in this particular indication.
Our current study provides evidence of a fucosylated ligand presented on the surface of the stressed RPE 
cells that binds CL-11 produced by the cells. Similarly, a fucosylated ligand has been found on adult mouse renal 
tubule cells also following hypoxic cell stress. This supports the concept of damage-associated carbohydrate rec-
ognition pattern(s) detected by CL-11 in different species and tissues. It is known that hypoxic stress induces 
alterations in the cell surface of endothelial cells, which could activate the complement system through the lec-
tin pathway66. Moreover, it has been shown that different rat retinal laminae show specific patterns of expres-
sion of glyco-conjugates, suggesting that their functions are common to the specific retinal regions concerned36. 
Resolution of the glycan structure recognised by CL-11 on human tissue is already underway, and it will be inter-
esting to compare the forms on stress-activated cells of different tissue origin, including the retina.
We have previously shown that blockade of the interaction of the L-fucose with CL-11, with either soluble 
L-fucose or fucosidase, resulted in an extensive reduction of CL-11 binding to stressed cells and complement 
activation28. Here we used the same approach to show that the inhibition of CL-11 binding results in less com-
plement activation on stressed-RPE cells. The finding that the L-fucose is a putative a damage-associated ligand 
present on the surface of epithelial cells following cell stress, is in line with a recent study showing that fucoidan, 
a heterogeneous group of sulphated polysaccharide with high content of L-fucose, reduces the secretion of the 
vascular endothelial growth factor (VEGF)67, the most important factor associated with in the development of 
wet AMD68, in retinal cells and the angiogenesis in vitro.
Like other collectin molecules, CL-11 uses MASP-2, which is physically associated with CL-11, to cleave C3 
and subsequently C5 prior to MAC formation. In fact, MASP-2 activity has been shown to be essential to mediate 
tissue injury in models of post-ischemic injury of heart, intestine and kidney in a C4-independent manner47. Our 
findings that MASP-2 protein expression occurs in iPS-RPE cells suggests that the iPS-RPE cells used for this 
study are self-sufficient as a source of complement components that drive complement activation downstream 
through the formation of the MAC. There is abundant evidence that sublytic amounts of MAC formed on epi-
thelial and other cell surfaces induces inflammasome activation, including the release of inflammatory cytokines, 
eicosanoids, collagen and other profibrotic factors69–71. We have not yet confirmed the extent of this activity 
and dependence on MAC formation to iPS-RPE cells, but plan to do so. Furthermore it should be noted that 
complement-independent effector functions also characterise the collectin family of pattern recognition mole-
cules; these include macrophage activation and local immune activation. Therefore it may be expected that CL-11 
will have complement-independent actions of relevance to the inflammatory status of RPE cells and potential 
application in eye disease. In summary, our study suggests that CL-11, a recently described component of innate 
immunity, is of relevance to the inflammatory status of RPE cells and may thus play an important role in AMD 
pathogenesis and the outcome of therapeutic interventions.
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